No HBLT interventions and, until the arrival of newer GLP1-RAs (e.g., semaglutide), no OM has shown meaningful reductions in MACE risk in patients with obesity and without T2D; although meta-analyses of randomized controlled trials (RCTs) evaluating GLP1RA use in patients with T2D have shown statistically significant MACE reductions [2, 13-15]. This evidence concerns the gene GCG and type 2 diabetes mellitus.